Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro

被引:23
|
作者
Baek, Jong Min [1 ]
Ahn, Sung-Jun [1 ]
Cheon, Yoon-Hee [2 ]
Lee, Myeung Su [3 ,5 ]
Oh, Jaemin [1 ,4 ,5 ]
Kim, Ju-Young [4 ]
机构
[1] Wonkwang Univ, Dept Anat, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[2] Wonkwang Univ, Ctr Metab Funct Regulat, Iksan 570749, South Korea
[3] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, South Korea
[4] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea
基金
新加坡国家研究基金会;
关键词
nicotinamide phosphoribosyltransferase; adipokine; osteoclast; osteoporosis; COLONY-ENHANCING FACTOR; CELLS; RANKL; BIOSYNTHESIS; PATHWAYS; PROTEINS; SURVIVAL; SIGNALS; MICE; FOS;
D O I
10.3892/mmr.2016.6069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The adipokine nicotinamide phosphoribosyltransferase (Nampt), also known as pre-B-cell colony-enhancing factor or the insulin-mimetic hormone visfatin, has a crucial role in the conversion of nicotinamide to nicotinamide mono nucleotide during biosynthesis of the coenzyme nicotinamide adenine dinucleotide. Previous reports have demonstrated the inhibitory effects of Nampt on osteoclast formation from human peripheral blood mononuclear cells and CD14(+) monocytes. However, the effects of Nampt on bone marrow macrophage (BMM)-derived osteoclastogenesis and its precise role in the process remain unclear. The present in vitro study used recombinant Nampt and BMMs as osteoclast precursors demonstrated that Nampt suppresses receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis by decreasing the phosphorylation of various early signal transducers, including c-Jun N-terminal kinase, Akt, glycogen synthase kinase-3 beta, Bruton's tyrosine kinase and phospholipase C gamma-2. In addition, western blotting and reverse transcription-quantitative polymerase chain reaction analysis indicated that Nampt downregulates the mRNA and protein expression levels of c-Fos and nuclear factor of activated T cells, cytoplasmic 1, leading to a decrease in the expression of osteoclast-specific genes including tartrate-resistant acid phosphatase, osteoclast-associated receptor and cathepsin K. However, the bone-resorbing activity of mature osteoclasts treated with Nampt was similar to untreated control osteoclasts. This finding indicates that Nampt exerts its anti-osteoclastogenic activity by targeting osteoclast precursor cells rather than mature osteoclasts. Consequently, the present study demonstrated that Nampt acts as a negative regulator of RANKL-mediated differentiation of BMMs into osteoclasts, suggesting the potential therapeutic targets to treat bone-related disorders such as osteoporosis.
引用
收藏
页码:784 / 792
页数:9
相关论文
共 50 条
  • [1] Yukmijihwang-tang Inhibits Receptor Activator for Nuclear Factor-κB Ligand-Induced Osteoclast Differentiation
    Shim, Ki-Shuk
    Ma, Choong Je
    Kim, Dong-Seon
    Ma, Jin Yeul
    JOURNAL OF MEDICINAL FOOD, 2011, 14 (11) : 1439 - 1447
  • [2] Cetylpyridinium Chloride Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclast Formation
    Zheng, Ting
    Chen, Ling
    Noh, A. Long Sae Mi
    Yim, Mijung
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (04) : 509 - 514
  • [3] Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis
    Liu, Yuanxin
    Zuo, Guilai
    Meng, Xin
    Gao, Xingxiao
    Zhang, Lihai
    Tang, Peifu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (05) : 4009 - 4016
  • [4] Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo
    Li, Zhuokai
    Li, De
    Chen, Xiaodong
    MEDICAL SCIENCE MONITOR, 2018, 24 : 1044 - 1053
  • [5] Pharmacological evaluation of imidazole-derived bisphosphonates on receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and function
    Lin, Jianguo
    Peng, Ying
    Liu, Qingzhu
    Li, Ke
    Lv, Gaochao
    Seimbille, Yann
    Huang, Gang
    Gao, Feng
    Qiu, Ling
    CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 97 (01) : 121 - 133
  • [6] Receptor activator of nuclear factor-κB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues
    Sasaki, Hideyuki
    Yamamoto, Hironori
    Tominaga, Kumiko
    Masuda, Kiyoshi
    Kawai, Tomoko
    Teshima-Kondo, Shigetada
    Matsuno, Kuniharu
    Yabe-Nishimura, Chihiro
    Rokutan, Kazuhito
    FREE RADICAL BIOLOGY AND MEDICINE, 2009, 47 (02) : 189 - 199
  • [7] Pentamidine Inhibits Titanium Particle-Induced Osteolysis In Vivo and Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Differentiation In Vitro
    Hye Jung Ihn
    Kiryeong Kim
    Hye-Sung Cho
    Eui Kyun Park
    Tissue Engineering and Regenerative Medicine, 2019, 16 : 265 - 273
  • [8] Pentamidine Inhibits Titanium Particle-Induced Osteolysis In Vivo and Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Differentiation In Vitro
    Ihn, Hye Jung
    Kim, Kiryeong
    Cho, Hye-Sung
    Park, Eui Kyun
    TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2019, 16 (03) : 265 - 273
  • [9] Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    ENDOCRINOLOGY, 2001, 142 (03) : 1290 - 1295
  • [10] Tetrandrine Prevents Bone Loss in Sciatic-Neurectomized Mice and Inhibits Receptor Activator of Nuclear Factor κB Ligand-Induced Osteoclast Differentiation
    Takahashi, Tatsuo
    Tonami, Yusuke
    Tachibana, Mami
    Nomura, Masaaki
    Shimada, Tsutomu
    Aburada, Masaki
    Kobayashi, Shinjiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (10) : 1765 - 1774